Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dextromethorphan/Bupropion: First Approval
Susan J. Keam
CNS Drugs (2022) Vol. 36, Iss. 11, pp. 1229-1238
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
John H. Krystal, Ege T. Kavalali, Lisa M. Monteggia
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 41-50
Open Access | Times Cited: 94
Prescribing in Older People
David G. Le Couteur, Sarah N. Hilmer, Nicholas Glasgow, et al.
(2025), pp. 627-712
Closed Access | Times Cited: 62
Depression and Anxiety Disorders
Oğuz Karamustafalıoğlu, Hüseyin Yumrukçal
(2025), pp. 335-476
Closed Access | Times Cited: 7
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Wenwen Duan, Dongmei Cao, Sheng Wang, et al.
Chemical Reviews (2023) Vol. 124, Iss. 1, pp. 124-163
Closed Access | Times Cited: 30
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M. Stahl, Sara De Martin, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1463-1476
Open Access | Times Cited: 23
The role of N-methyl-D-aspartate glutamate receptors in Alzheimer’s disease: From pathophysiology to therapeutic approaches
Wenying Liu, Yan Li, Tan Zhao, et al.
Progress in Neurobiology (2023) Vol. 231, pp. 102534-102534
Closed Access | Times Cited: 17
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 7
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 14
Engineered Imine Reductase for Asymmetric Synthesis of Dextromethorphan Key Intermediate
Xiaofeng Lin, Yixuan Li, Zefei Xu, et al.
Organic Letters (2024) Vol. 26, Iss. 21, pp. 4463-4468
Closed Access | Times Cited: 4
Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study
Lingjing Yuan, Jianping He, Xiangyu Li
European Journal of Clinical Pharmacology (2025)
Closed Access
Structural insights into gating mechanism and allosteric regulation of NMDA receptors
Enjiang Wu, Jilin Zhang, Jiwei Zhang, et al.
Current Opinion in Neurobiology (2023) Vol. 83, pp. 102806-102806
Closed Access | Times Cited: 10
Mechanisms of NMDA receptor inhibition by vortioxetine – comparison with fluoxetine
Arseniy S. Zhigulin, Oleg I. Barygin
European Journal of Pharmacology (2025), pp. 177460-177460
Closed Access
Simultaneous enantioselective determination of 2-, 3-, and 4-methylmethcathinones; their isomers; and major phase-1 metabolites in oral fluid of drug abusers using enantioselective high-performance liquid chromatography-tandem mass spectrometry
Giorgi Kobidze, Alfredo Fabrizio Lo Faro, Aurora Balloni, et al.
Analytical and Bioanalytical Chemistry (2025)
Closed Access
Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics
Sara Castanheira, Catarina Gomes, Joana Bicker, et al.
Drug Discovery Today (2025), pp. 104371-104371
Open Access
Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders
Kiarash Eskandari, Sara-Maude Bélanger, Véronik Lachance, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 5, pp. 700-700
Open Access
A novel NMDA receptor modulator: the antidepressant effect and mechanism of GW043
Murezati Tiliwaerde, Nana Gao, Yaqi Yang, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 2
Open Access | Times Cited: 3
Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol
Shampa Maji, Debadatta Mohapatra, Monalisa Jena, et al.
BMJ Open (2024) Vol. 14, Iss. 4, pp. e080500-e080500
Open Access | Times Cited: 2
Bitter tastants relax the mouse gallbladder smooth muscle independent of signaling through tuft cells and bitter taste receptors
Maryam Keshavarz, Anna-Lena Ruppert, Mirjam Meiners, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Berend Olivier, Berend Olivier
Advances in experimental medicine and biology (2024), pp. 49-66
Closed Access | Times Cited: 2
Innovative five eco-friendly spectrophotometric methods for simultaneous determination of the recently FDA-approved combination, dextromethorphan and bupropion in co-formulated tablets and biological fluids
Aya Saad Radwan, Mohamed M. Salim, Fathalla Belal, et al.
Sustainable Chemistry and Pharmacy (2024) Vol. 42, pp. 101796-101796
Closed Access | Times Cited: 2
Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment‐resistant depression and psychiatric comorbidities
Bruno Pedraz‐Petrozzi, Michael Deuschle, Maria Gilles
Clinical Case Reports (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 6
Management of neuropsychiatric symptoms in dementia
Davangere P. Devanand
Current Opinion in Neurology (2023) Vol. 36, Iss. 5, pp. 498-503
Closed Access | Times Cited: 5
Mechanisms of NMDA Receptor Inhibition by Sepimostat—Comparison with Nafamostat and Diarylamidine Compounds
Arseniy S. Zhigulin, Oleg I. Barygin
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15685-15685
Open Access | Times Cited: 5
Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2)
Harold A. Sackeïm, Scott T. Aaronson, Mark Bunker, et al.
Journal of Psychiatric Research (2024) Vol. 176, pp. 325-337
Open Access | Times Cited: 1
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial
Shampa Maji, Archana Mishra, Debadatta Mohapatra, et al.
Psychiatry Research (2024) Vol. 342, pp. 116257-116257
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top